Article
Oncology
Yuma Sakamoto, Takashi Ishida, Ayako Masaki, Takayuki Murase, Eiichi Ohtsuka, Morishige Takeshita, Reiji Muto, Hiromi Iwasaki, Asahi Ito, Shigeru Kusumoto, Nobuaki Nakano, Masahito Tokunaga, Kentaro Yonekura, Yukie Tashiro, Shinsuke Iida, Atae Utsunomiya, Ryuzo Ueda, Hiroshi Inagaki
Summary: This study found that CCR7 gene alterations are significantly associated with survival rates in adult T-cell leukemia/lymphoma (ATL) patients receiving mogamulizumab treatment. However, CCR7 alterations have no significant impact on overall survival in the entire cohort or on patients receiving allogeneic hematopoietic stem cell transplantation (HSCT). Additionally, patients with CCR4 alterations but lacking CCR7 alterations have significantly better survival rates after receiving mogamulizumab-containing treatments.
HEMATOLOGICAL ONCOLOGY
(2022)
Article
Hematology
Norio Tanaka, Seiichi Mori, Kazuma Kiyotani, Yuki Ota, Osamu Gotoh, Shigeru Kusumoto, Nobuaki Nakano, Youko Suehiro, Asahi Ito, Ilseung Choi, Eiichi Ohtsuka, Michihiro Hidaka, Kisato Nosaka, Makoto Yoshimitsu, Yoshitaka Imaizumi, Shinsuke Iida, Atae Utsunomiya, Tetsuo Noda, Hiroyoshi Nishikawa, Ryuzo Ueda, Takashi Ishida
Summary: By conducting molecular analysis on adult T-cell leukemia/lymphoma (ATL) patients, it was found that CCR4 alterations were associated with better clinical response and overall survival, while TP53, CD28, and CD274 alterations were associated with worse overall survival. This study contributes to the establishment of precision medicine using mogamulizumab in ATL patients.
Article
Hematology
Takafumi Shichijo, Kisato Nosaka, Hiro Tatetsu, Yusuke Higuchi, Shinya Endo, Yoshitaka Inoue, Kosuke Toyoda, Yoshitaka Kikukawa, Toshiro Kawakita, Jun-ichirou Yasunaga, Masao Matsuoka
Summary: This retrospective study analyzed the clinical outcomes of 39 transplant-ineligible patients with untreated aggressive ATL. The results showed that first-line Mog-containing treatment can significantly improve overall survival compared to chemotherapy alone, even in elderly patients.
BRITISH JOURNAL OF HAEMATOLOGY
(2022)
Article
Oncology
Rosanne Ottevanger, Sylvia van Beugen, Andrea W. M. Evers, Rein Willemze, Maarten H. Vermeer, Koen D. Quint
Summary: This study provides insights into the impact of E-CTCL and mogamulizumab treatment on patients' quality of life and treatment satisfaction. Most patients had positive expectations and experienced improvements in symptoms, emotions, functioning, and overall quality of life. Mogamulizumab seems to be an effective treatment with high treatment satisfaction.
Article
Oncology
Tomonori Higuchi, Yumiko Hashida, Kazuhiko Matsuo, Kosuke Kitahata, Takako Ujihara, Ichiro Murakami, Takashi Nakayama, Masanori Daibata
Summary: Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphoma associated with chronic inflammation (DLBCL-CI) develops in the setting of long-standing inflammation. This type of lymphoma may have specific expression profiles of chemokines involved in the pathogenesis of DLBCL-CI. EBV-positive pyothorax-associated lymphoma (PAL) is a prototype of DLBCL-CI and represents a valuable model for the study of this disease category.
Article
Oncology
Tatsuro Jo, Kazuhiro Noguchi, Takahiro Sakai, Ritsuko Kubota-Koketsu, Sadaharu Irie, Masatoshi Matsuo, Jun Taguchi, Kuniko Abe, Kazuto Shigematsu
Summary: This study investigated the characteristics of long-term survivors with Adult T-cell leukemia/lymphoma (ATLL) and found that Tax-specific memory CTLs may eradicate ATLL cells and prevent ATLL relapse in the long term, possibly in conjunction with anticancer agents. Strong activation of cellular immunity, such as infection with herpes virus, appears to be necessary to induce a large number of Tax-specific CTLs.
Article
Hematology
Lucy B. Cook, Adrienne A. Phillips
Summary: ATL is an aggressive T-cell malignancy with limited survival outcomes with chemotherapy, but novel therapies like mogamulizumab show promise for different ATL subtypes. The implementation of molecular methods may guide diagnosis and treatment, but universal availability remains a challenge worldwide.
Article
Hematology
Sara Beygi, George E. Duran, Sebastian Fernandez-Pol, Alain H. Rook, Youn H. Kim, Michael S. Khodadoust
Summary: Resistance to mogamulizumab in mycosis fungoides and Sezary syndrome is often associated with loss of CCR4 expression and emergence of CCR4 genomic alterations. This finding has significant implications for the management and monitoring of patients receiving mogamulizumab and the development of future CCR4-directed therapies.
Article
Immunology
Mohammed J. S. Al-Ghabban, Nagham Y. Al-Bayati, Qasim S. Al-Mayah, Hisham Y. Al-Matubsi
Summary: The GG genotype of CTLA-4+49G/A polymorphism was found to be significantly less common in CL patients, with the G allele being more common in controls. Newly diagnosed CL patients had significantly higher serum sCTLA-4 levels, which may serve as an additional diagnostic tool.
MICROBIAL PATHOGENESIS
(2021)
Article
Multidisciplinary Sciences
Mario Bunse, Janina Pfeilschifter, Julia Bluhm, Maria Zschummel, Jara J. Joedicke, Anthea Wirges, Helen Stark, Vivien Kretschmer, Markus Chmielewski, Wolfgang Uckert, Hinrich Abken, Joerg Westermann, Armin Rehm, Uta E. Hoepken
Summary: The study demonstrates that CAR-T cells targeting CXCR5 effectively inhibit tumor growth by depleting both B cells and follicular T helper cells in lymphoma models, suggesting a promising treatment strategy for nodal B-NHLs.
NATURE COMMUNICATIONS
(2021)
Review
Biochemistry & Molecular Biology
Fumi Miyagawa, Hideo Asada
Summary: For severe cutaneous adverse reactions (SCARs) like Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN) and drug-induced hypersensitivity syndrome (DIHS)/drug reaction with eosinophilia and systemic symptoms (DRESS), analyzing distinct chemokine profiles can aid in their diagnosis and treatment. It is crucial to identify new therapeutic targets for SCARs, with chemokines playing a key role in the pathogenesis and adjuvant diagnosis of these conditions. Additionally, the association between human herpesvirus 6 (HHV-6) and DIHS/DRESS, as well as the possible roles of chemokine/chemokine receptor homologs encoded by HHV-6 in the pathogenesis, are areas of increasing interest.
Article
Hematology
Akio Onishi, Shigeo Fuji, Shigehisa Kitano, Akiko Miyagi Maeshima, Kinuko Tajima, Junko Yamaguchi, Ichiro Kawashima, Akihisa Kawajiri, Tomonari Takemura, Ayumu Ito, Takashi Tanaka, Keiji Okinaka, Yoshihiro Inamoto, Saiko Kurosawa, Sung-Won Kim, Wataru Munakata, Dai Maruyama, Kensei Tobinai, Takahiro Fukuda
Summary: This study aims to identify the association between the expression profile of immune checkpoint proteins on ATLL cells and clinical outcomes. The analysis shows that CTLA-4, PD-1, and PD-L1 expressions were adverse prognostic factors in patients with aggressive ATLL.
ANNALS OF HEMATOLOGY
(2022)
Article
Dermatology
N. A. Trum, J. Zain, X. U. Martinez, V Parekh, M. Afkhami, F. Abdulla, K. R. Carson, S. T. Rosen, C. L. Bennett, C. Querfeld
Summary: MAR incidence is higher in CTCL patients than previously reported. Diagnosis and treatment of MAR should be emphasized to improve outcomes.
BRITISH JOURNAL OF DERMATOLOGY
(2022)
Article
Dermatology
Keiko Nakahashi, Kaito Nihira, Miyoko Suzuki, Toshihiko Ishii, Kazuhiro Masuda, Kiyotoshi Mori
Summary: In this study, a new mouse model of CTCL was developed to evaluate the efficacy of PUVA therapy, and the combination treatment of PUVA and mogamulizumab showed greater antitumor activity than either monotherapy.
EXPERIMENTAL DERMATOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Tomohiro Kozako, Naho Kato, Takeo Ohsugi, Yu-ichiro Uchida, Makoto Yoshimitsu, Kenji Ishitsuka, Yasuki Higaki, Haruna Sato, Akiyoshi Aikawa, Shin-ichiro Honda
Summary: In this study, researchers found that SRT1720 can induce cell death in adult T-cell leukemia/lymphoma (ATL) cells through apoptosis and autophagy, and it exhibits anti-tumor activity.
Article
Oncology
Masahito Tokunaga, Hirofumi Uto, Shogo Takeuchi, Nobuaki Nakano, Ayumu Kubota, Mayumi Tokunaga, Yoshifusa Takatsuka, Masao Seto, Akio Ido, Atae Utsunomiya
LEUKEMIA & LYMPHOMA
(2017)
Article
Hematology
Masao Ogata, Kuniko Takano, Yukiyoshi Moriuchi, Tadakazu Kondo, Toshimitsu Ueki, Nobuaki Nakano, Takehiko Mori, Nobuhiko Uoshima, Koji Nagafuji, Satoshi Yamasaki, Yasuhiko Shibasaki, Rika Sakai, Koji Kato, Ilseung Choi, Yumi Jo, Tetsuya Eto, Shinichi Kako, Kumi Oshima, Takahiro Fukuda
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
(2018)
Letter
Oncology
Ayumu Kubota, Nobuaki Nakano, Masahito Tokunaga, Takayoshi Miyazono, Mayumi Tokunaga, Torahiko Makino, Shogo Takeuchi, Kentaro Yonekura, Yoshifusa Takatsuka, Atae Utsunomiya
HEMATOLOGICAL ONCOLOGY
(2019)
Article
Hematology
Makoto Yoshimitsu, Shigeo Fuji, Atae Utsunomiya, Nobuaki Nakano, Ayumu Ito, Yoshikiyo Ito, Toshihiro Miyamoto, Youko Suehiro, Toshiro Kawakita, Yukiyoshi Moriuchi, Hirohisa Nakamae, Yoshinobu Kanda, Tatsuo Ichinohe, Takahiro Fukuda, Yoshiko Atsuta, Koji Kato
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
(2020)
Article
Hematology
Nobuaki Nakano, Atae Utsunomiya, Keitaro Matsuo, Noriaki Yoshida, Masao Seto, Kouichi Ohshima, Hiroshi Fujiwara, Shigeo Fuji, Yoshifusa Takatsuka, Ayumu Ito, Toshihiro Miyamoto, Youko Suehiro, Hirohisa Nakamae, Yasushi Sawayama, Mitsuhiro Yuasa, Yasuhiko Miyazaki, Shuichi Ota, Kazunori Imada, Takahiro Fukuda, Tatsuo Ichinohe, Yoshiko Atsuta, Koji Kato
Summary: This study investigated the impact of chromosomal abnormalities on the survival of ATL patients after allo-HSCT, and found that certain structural breakpoints were independent risk factors for overall survival and ATL-related death.
Article
Hematology
Nobuaki Nakano, Yoshifusa Takatsuka, Ayumu Kubota, Masahito Tokunaga, Takayoshi Miyazono, Tomohisa Tabuchi, Jun Odawara, Mayumi Tokunaga, Torahiko Makino, Shogo Takeuchi, Yoshikiyo Ito, Atae Utsunomiya
Summary: Cord blood transplantation with non-TBI-RIC using Flu/Mel is a promising treatment strategy for ATLL patients, especially in older patients.
INTERNATIONAL JOURNAL OF HEMATOLOGY
(2021)
Correction
Hematology
Nobuaki Nakano, Yoshifusa Takatsuka, Ayumu Kubota, Masahito Tokunaga, Takayoshi Miyazono, Tomohisa Tabuchi, Jun Odawara, Mayumi Tokunaga, Torahiko Makino, Shogo Takeuchi, Yoshikiyo Ito, Atae Utsunomiya
INTERNATIONAL JOURNAL OF HEMATOLOGY
(2021)
Article
Biophysics
Yoshitaka Inoue, Nobuaki Nakano, Shigeo Fuji, Tetsuya Eto, Toshiro Kawakita, Youko Suehiro, Toshihiro Miyamoto, Yasushi Sawayama, Naoyuki Uchida, Tadakazu Kondo, Junya Kanda, Yoshiko Atsuta, Takahiro Fukuda, Makoto Yoshimitsu, Koji Kato
Summary: For younger patients undergoing allo-HCT for ATL, there is no significant difference between RIC and MAC regimens in terms of relapse risk, non-relapse mortality, and overall mortality. Among RIC regimens, Flu/Mel-based regimens may be beneficial for patients at high risk of relapse.
BONE MARROW TRANSPLANTATION
(2021)
Article
Hematology
Yuma Sakamoto, Takashi Ishida, Ayako Masaki, Takayuki Murase, Morishige Takeshita, Reiji Muto, Hiromi Iwasaki, Asahi Ito, Shigeru Kusumoto, Nobuaki Nakano, Masahito Tokunaga, Kentaro Yonekura, Yukie Tashiro, Shinsuke Iida, Atae Utsunomiya, Ryuzo Ueda, Hiroshi Inagaki
Summary: TP53 mutations are associated with unfavorable prognosis of ATL, regardless of treatment strategy. The establishment of alternative modalities to overcome the adverse impact of TP53 mutations in patients with ATL is required.
BRITISH JOURNAL OF HAEMATOLOGY
(2021)
Letter
Biophysics
Atae Utsunomiya, Masahito Tokunaga, Nobuaki Nakano, Hiroshi Fujiwara, Toshihiro Miyamoto, Masao Ogata, Yasuhiko Miyazaki, Kenji Ishitsuka, Emiko Sakaida, Hirofumi Taji, Toshio Wakayama, Tatsuo Ichinohe, Takahiro Fukuda, Yoshiko Atsuta, Koji Kato, Makoto Yoshimitsu
BONE MARROW TRANSPLANTATION
(2022)
Article
Hematology
Kisato Nosaka, Shigeru Kusumoto, Nobuaki Nakano, Ilseung Choi, Makoto Yoshimitsu, Yoshitaka Imaizumi, Michihiro Hidaka, Hidenori Sasaki, Junya Makiyama, Eiichi Ohtsuka, Tatsuro Jo, Masao Ogata, Asahi Ito, Kentaro Yonekura, Hiro Tatetsu, Takeharu Kato, Toshiro Kawakita, Youko Suehiro, Kenji Ishitsuka, Shinsuke Iida, Takaji Matsutani, Atae Utsunomiya, Ryuzo Ueda, Takashi Ishida
Summary: The MIMOGA study showed that a lower percentage of CD2(-)CD19(+) B cells in PBMC was associated with unfavorable prognosis in patients with adult T-cell leukaemia-lymphoma. Analysis of IgG heavy-chain repertoire revealed a restricted repertoire in ATL patients compared to healthy individuals, with IgG diversity index correlating positively with B cell proportions. Higher serum soluble interleukin-2 receptor levels and lower IgG repertoire diversity were identified as significant factors affecting overall survival in patients. This study emphasizes the importance of humoral immune responses in patients undergoing mogamulizumab-containing treatment for ATL.
BRITISH JOURNAL OF HAEMATOLOGY
(2022)
Letter
Biophysics
Masahito Tokunaga, Nobuaki Nakano, Shigeo Fuji, Atsushi Wake, Atae Utsunomiya, Ayumu Ito, Tetsuya Eto, Toshiro Kawakita, Yasuo Mori, Yukiyoshi Moriuchi, Youko Suehiro, Yasuhiko Miyazaki, Naoyuki Uchida, Yasushi Sawayama, Kenji Ishitsuka, Junya Kanda, Takafumi Kimura, Tatsuo Ichinohe, Yoshiko Atsuta, Takahiro Fukuda, Makoto Yoshimitsu, Koji Kato
BONE MARROW TRANSPLANTATION
(2023)
Article
Biophysics
Yoshitaka Inoue, Satoko Morishima, Koji Kato, Ayumu Ito, Nobuaki Nakano, Takuro Kuriyama, Toshiro Kawakita, Yasuo Mori, Youko Suehiro, Hidehiro Itonaga, Yasuhiko Miyazaki, Kazunori Imada, Shouhei Tomori, Junya Kanda, Tatsuo Ichinohe, Yoshiko Atsuta, Takahiro Fukuda, Makoto Yoshimitsu
Summary: This nationwide retrospective study in Japan examined the effects of HLA-mismatched unrelated transplantation on adult T-cell leukemia-lymphoma patients. The study compared outcomes between patients who received 6/6 antigen-matched related donor (MRD) transplants, 8/8 allele-matched unrelated donor (8/8MUD) transplants, and 1 allele-mismatched unrelated donor (7/8MMUD) transplants. The results showed that 7/8MMUD can be considered as an acceptable alternative donor when an HLA-matched donor is not available.
BONE MARROW TRANSPLANTATION
(2023)
Article
Hematology
Akihiko Arai, Makoto Yoshimitsu, Maki Otsuka, Yoshikiyo Ito, Takayoshi Miyazono, Nobuaki Nakano, Kosuke Obama, Hidetoshi Nakashima, Shuichi Hanada, Satsuki Owatari, Daisuke Nakamura, Masahito Tokunaga, Yuhei Kamada, Atae Utsunomiya, Koichi Haraguchi, Maiko Hayashida, Satoshi Fujino, Jun Odawara, Tomohisa Tabuchi, Shinsuke Suzuki, Heiichiro Hamada, Yoshiko Kawamoto, Yuichiro Uchida, Miho Hachiman, Kenji Ishitsuka
Summary: This study evaluated the clinical characteristics of triple-negative essential thrombocythemia (ET) and identified novel driver mutations. Among 119 ET patients, 20 (16.8%) had no canonical JAK2/CALR/MPL mutations. The study identified seven putative driver mutations, including previously reported candidate driver mutations and germline mutations.
EUROPEAN JOURNAL OF HAEMATOLOGY
(2023)
Letter
Oncology
Hiroaki Hiramatsu, Rui Yokomori, Liu Shengyi, Norio Tanaka, Seiichi Mori, Kazuma Kiyotani, Osamu Gotoh, Shigeru Kusumoto, Nobuaki Nakano, Youko Suehiro, Asahi Ito, Ilseung Choi, Eiichi Ohtsuka, Michihiro Hidaka, Kisato Nosaka, Makoto Yoshimitsu, Yoshitaka Imaizumi, Shinsuke Iida, Atae Utsunomiya, Tetsuo Noda, Hiroyoshi Nishikawa, Ryuzo Ueda, Takaomi Sanda, Takashi Ishida